Publications by authors named "R Jakesz"
Purpose: The Clinical Treatment Score post-5 years (CTS5) is an easy-to-use tool estimating the late distant recurrence (LDR) risk in patients with hormone receptor-positive breast cancer after 5 years of endocrine therapy (ET). Apart from evaluating the prognostic value and calibration accuracy of CTS5, the aim of this study is to clarify if this score is able to identify patients at higher risk for LDR who will benefit from extended ET.
Methods: Prognostic power, calibration, and predictive value of the CTS5 was tested in patients of the prospective ABCSG-06 and -06a trials (n = 1254 and 860 patients, respectively).
Article Synopsis
- Adjuvant aromatase inhibitors for hormone receptor-positive breast cancer can lead to increased osteoporosis and fractures; however, the ABCSG-18 trial indicates that denosumab can mitigate these effects.
- In this phase 3 trial involving 3,425 postmenopausal patients, denosumab treatment showed a significant improvement in disease-free survival (DFS) and bone metastasis-free survival (BMFS) compared to placebo over an 8-year median follow-up.
- The final analysis confirmed long-term benefits with denosumab, enhancing overall survival (OS) and showing no new toxicities associated with its use.
Purpose: Estrogen receptor (ER) expression is a prognostic parameter in breast cancer, and a prerequisite for the use of endocrine therapy. In ER+ early breast cancer, however, no receptor-associated biomarker exists that identifies patients with a particularly favorable outcome. We have investigated the value of ESR1 amplification in predicting the long-term clinical outcome in tamoxifen-treated postmenopausal women with endocrine-responsive breast cancer.
View Article and Find Full Text PDFIntroduction: Oncoplastic techniques allow resection of larger tumors, permitting breast conservation in cases otherwise requiring mastectomy. We sought to prospectively compare quality of life (QoL) in patients undergoing oncoplastic surgery as compared to conventional breast conservation (CBC) or mastectomy is lacking.
Methods: Patients diagnosed with BIRADS IV-VI lesion were eligible if resection of ≥10% of the breast volume was planned.